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A decade ago, Nick Fox and colleagues [1] used sample 
size estimates for hypothetical disease-modifying clinical 
trials to call attention to the important value of magnetic 
resonance imaging (MRI)-based imaging biomarkers for 
Alzheimer disease (AD). Since then, this approach has 
been employed to demonstrate the potential value of new 
methods for measuring anatomic, metabolic, and other 
putative AD biomarkers [2]. A new paper illustrates 
progress and challenges in this area [3].
Th  e authors measured longitudinal change in cortical 
and subcortical volume with an interesting new method 
that takes advantage of a precise image registration 
algorithm (comparable to tensor-based morphometry, or 
TBM). A so-called volume-change ﬁ  eld is produced at 
each voxel and then is averaged over a set of—in some 
cases large—a priori-deﬁ  ned anatomic regions of interest 
(ROIs) to obtain the percentage change from baseline. 
Th  is averaging step is somewhat puzzling, however, 
particularly given the stated precision of registration and 
concept of this method as providing ‘subregion’ measures. 
Th  e  a priori atlas [4] provides a valuable service in that it 
does an excellent job of automating a cumbersome 
process of identifying neuroanatomic ROIs in individual 
scans. However, many of the cortical ROIs are quite large 
and most neuro  degenerative diseases do not respect the 
anatomic boundaries of these ROIs—only subregions 
tend to be aﬀ  ected, and some eﬀ  ects span multiple ROIs. 
Th   us, the power of this precise registration method may 
be reduced by constraining it to anatomic ROIs, rather 
than to ROIs generated from the known eﬀ  ects of AD 
itself (‘disease signature’ eﬀ   ects), such as have been 
described for both MRI [5,6] and ﬂ  uorodeoxyglucose-
positron emission tomo  graphy (FDG-PET) data [7]. Th  is 
point is illustrated in a recent TBM study [8] showing 
that an anatomically deﬁ  ned ROI in the temporal lobe 
required consistently higher samples than a ‘disease 
signature’ ROI deﬁ  ned from an independent longitudinal 
AD patient sample (Table 1 of [8]).
Although diﬀ   erences in sample size estimation 
methods make it diﬃ   cult to directly compare the present 
study [3] to that of Fox and colleagues (2000) [1], a 
cursory examination of the whole-brain measure in AD 
patients from Table 1 of the present study (n = 189) with 
Table 1 of Fox and colleagues (n = 168) does not suggest 
an obvious advantage. With more closely matched sample 
size estimation calculations, comparison with the recent 
TBM study [8] demonstrates that the present method 
requires consistently larger sample sizes for both AD and 
mild cognitive impairment. (Compare Tables 1 and 2 of 
the present study [3] with Table 1 of the TBM study [8].) 
Nevertheless, the new method ultimately may make 
important contributions with further development.
How can we decide whether a new marker adds value? 
Sample size estimation is one approach since it reﬂ  ects 
the size of the biologic or clinical eﬀ  ect of interest and its 
variability (subsuming both biologic and measurement 
variability).
One important challenge in comparing papers using 
such analyses is that many of the investigator-speciﬁ  ed 
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A critical goal of Alzheimer disease research is to 
identify disease biomarkers that can be used in clinical 
trials to assist in the adjudication of treatment eff  ects. 
While clinical validation remains a goal for many 
potential Alzheimer disease biomarkers, the rapid 
proliferation of markers has sparked comparative 
eff  orts as well. New data acquisition methods and 
sophisticated image-processing algorithms are 
poised to make a substantial impact on our ability 
to make precise measurements of the structure and 
function of regions within the living human brain and 
their connections and chemical composition. This 
commentary provides a perspective on a recently 
published paper and how it illustrates progress and 
challenges in the fi  eld.
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Larger or smaller sample size estimates can be derived 
from the same measures simply by choosing diﬀ  erent 
hypothetical drug eﬀ  ects. If sample size estimates are not 
recalculated using original data, it can be diﬃ   cult  to 
directly compare such measures, requiring readers to 
resort to comparing the atrophy rates and standard 
devia  tions, which also may be variably reported.
In large part because of the profound advances in 
infrastructure and standards being developed by the 
Alzheimer’s Disease Neuroimaging Initiative (ADNI), it 
is now possible to eﬃ     ciently perform comparisons of 
increasingly sophisticated measures derived from com-
pu  tational processing of MRI and PET data. Yet it can 
still be diﬃ   cult to compare measures because diﬀ  erent 
subsets of subjects may be included in any analysis. 
Laurel Beckett, Danielle Harvey, and colleagues aﬃ   liated 
with the ADNI biostatistics core are ﬁ  nishing an analysis 
that emphasizes the need to compare markers on a 
common set of subjects and demonstrates a method not 
only for characterizing biomarkers but also for statis-
tically testing for diﬀ  erences between measures. Th  ese 
important advances should provide a framework that 
makes it easier to determine the pros and cons of new 
imaging analytic methods, which are advancing in at least 
two domains.
First, they are becoming more reﬁ  ned with respect to 
anatomy. Since the pioneering eﬀ   orts of the neuro-
anatomist Constantin von Economo, who not only 
exhaustively mapped cortical cytoarchitecture but also 
painstakingly measured the thickness of cortical regions 
and laminae [9], anatomists have been interested in 
measures of the size of diﬀ  erent brain regions. Although 
anatomists and pathologists over the years have observed 
cortical thinning in AD [10,11], it has proven very 
challenging to measure in vivo. Th  ese issues have been 
largely solved in recent years through advanced compu-
tational procedures [12-14]. Since the volume of a gyral 
cortical region reﬂ  ects both its thickness and surface area 
and since AD appears to aﬀ  ect thickness more promi-
nently than surface area [15] (although this issue deserves 
further study), it also stands to reason that measures of 
thickness may be particularly sensitive to neurodegenera-
tive disease eﬀ   ects. It is somewhat surprising that 
computational methods perform as well as they do in 
detecting submillimeter disease eﬀ   ects with raw voxel 
sizes of at least 1 mm; the precision of these measures 
will undoubtedly improve as the resolution of MRI data 
acquisition improves.
Second, advanced methods for mapping the spatial 
patterns of disease will likely enhance our ability to diﬀ  er-
entiate the eﬀ  ects of one disease from those of another or 
from normal aging. A number of these methods are being 
developed and they are derived mostly from machine 
learning and pattern recognition algorithms and 
increasingly are being used in applications such as face or 
voice recognition. Initial applications of these methods to 
AD and related disorders have been very promising [16-
18], and these types of procedures will likely have an 
important impact on improving the speciﬁ  city of imaging 
biomarkers in AD.
Ultimately, the goal of this research is to enable disease-
modifying treatments to be identiﬁ  ed more eﬃ   ciently. A 
large and growing community of investigators in the ﬁ  eld 
believes that we not only need to measure brain changes 
that can provide a glimpse of any such beneﬁ  ts of a given 
intervention but also need to realize the complexities of 
linking these changes to clinical beneﬁ  t [19].
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